 |
|
Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso, Heon Ju Lee
Korean J Intern Med. 2018;33(1):91-101. Published online 2017 Dec 13 DOI: https://doi.org/10.3904/kjim.2016.111
|
|
Citations to this article as recorded by
 A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review
Renato Ferreira-da-Silva, Joana Reis-Pardal, Manuela Pinto, Matilde Monteiro-Soares, Bernardo Sousa-Pinto, Manuela Morato, Jorge Junqueira Polónia, Inês Ribeiro-Vaz
Drug Safety.2024; 47(12): 1203. CrossRef First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide
Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma‐Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie‐Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, K. Rajender Reddy
Hepatology Communications.2022; 6(8): 1881. CrossRef
|